Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q9JT
|
|||
| Former ID |
DAP000424
|
|||
| Drug Name |
Metyrapone
|
|||
| Synonyms |
MYT; Mepyrapone; Metapirone; Metapyron; Methapyrapone; Methbipyranone; Methopirapone; Methopyrapone; Methopyrinine; Methopyrone; Metirapona; Metopiron; Metopirone; Metopyrone; Metroprione; Metyrapon; Metyraponum; Alliance Brand of Metyrapone; Metyrapone Alliance Brand; Metyrapone Novartis Brand; Novartis Brand of Metyrapone; Su 4885; METOPIRONE (TN); Metirapona [INN-Spanish]; Metopirone (TN); Metyraponum [INN-Latin]; Su-4885; Metyrapone (JP15/USP/INN); Metyrapone [USAN:INN:BAN:JAN]; 1,2-Di-3-pyridyl-2-methyl-1-propanone; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; 2-Methyl-1,2-di-3-pyridyl-1-propanone; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; 2-methyl-1,2-dipyridin-3-ylpropan-1-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cushing disease [ICD-11: 5A70; ICD-10: E24; ICD-9: 255] | Approved | [1], [2] | |
| Therapeutic Class |
Antimetabolites
|
|||
| Company |
Norvatis Phamaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H14N2O
|
|||
| Canonical SMILES |
CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2
|
|||
| InChI |
1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3
|
|||
| InChIKey |
FJLBFSROUSIWMA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 54-36-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9414, 86475, 834067, 866374, 3139656, 4904672, 7847476, 7889107, 7979980, 8152614, 10526331, 11112126, 11466932, 11468052, 11486683, 14749227, 24351138, 24888424, 26697184, 26709953, 26755473, 29223280, 46504862, 47193698, 47589141, 48110604, 48185138, 48334651, 48416273, 49699202, 50024064, 50647167, 53789558, 56320925, 56323421, 57322178, 57394052, 85787390, 92125714, 92308195, 93167100, 103243148, 103914631, 103937534, 104169960, 104305644, 117362532, 118810074, 121362605, 121363385
|
|||
| ChEBI ID |
CHEBI:44241
|
|||
| ADReCS Drug ID | BADD_D01450 | |||
| SuperDrug ATC ID |
V04CD01
|
|||
| SuperDrug CAS ID |
cas=000054364
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Steroid 11-beta-hydroxylase (CYP11B1) | Target Info | Inhibitor | [3] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Mineralocorticoid biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Pathwhiz Pathway | Steroidogenesis | |||
| Reactome | Glucocorticoid biosynthesis | |||
| Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | |||
| Oxidation by Cytochrome P450 | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| Corticotropin-releasing hormone | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5224). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012911. | |||
| REF 3 | Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.